anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, gastroenterology. SUBSTANCE: in case of adenomatous and hyperplastic polyps of IY type method deals with polyp electroexcision at endoscopy. Then by several injections 10000 International Units of leukinferon is introduced into submucosal gastric layer. The whole dose of preparation is distributed around a scab. Analogous injections are repeated in a day for 2-4 days. At adenomatous and hyperplastic polyps of IY and III types 10000 International Units of leukinferon is introduced into a polyp by several pricks. The dose is steadily distributed along the whole volume of neoplasm. Analogous injections are repeated in a day for 3-5 times per a course. In all cases local therapy is combined with injection of leukinferon into rectum as suppositories per 1 suppository which contains 40000 International Units of preparation in 1-3 days. There are 5-10 suppositories per a course. EFFECT: decreased traumaticity of interference, improved prophylaxis of relapses at endoscopic treatment of gastric polyps.
Two-arm, placebo-controlled pilot study to obtain preliminary estimates of treatment effects of minocycline in patients with non small cell lung cancer (NSCLC) being consented for concurrent chemoradiation (CXRT). Placebo capsules taken by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy. Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
A blood pressure prediction method and an electronic device using the same are provided. The method includes the following steps. A training data set is collected. A first blood pressure prediction model is established according to the training data set. Hemodialysis parameter data of a target patient is received, wherein the hemodialysis parameter data includes a first hemodialysis parameter at a previous time point and a second hemodialysis parameter at a current time point. A hemodialysis parameter variation amount between the first hemodialysis parameter and the second hemodialysis parameter is calculated. The hemodialysis parameter variation amount is provided to the first blood pressure prediction model to generate a prediction blood pressure variation associated with a next time point. An operation is performed according to the prediction blood pressure variation of the target patient.
A composition for nasal administration to animals, including humans. Applicants' composition includes lysozyme in combination with zinc. In certain embodiments, the composition further includes one or more anthelmentic compounds. A method to treat animals, including humans, having a pulmonary bacterial infection by delivering a therapeutically effective amount of lysozyme to the animal's nasal pharynx. A method to treat animals, including humans, having a viral infection by delivering a therapeutically effective amount of zinc to the animal's nasal pharynx. In certain embodiments, the method further includes delivering lysozyme to the animal's nasal pharynx.
The vascular endothelial growth factor (VEGF) family plays a crucial role in cancer progression, but the prognostic significance and biological functions of VEGF family members in colon adenocarcinoma (COAD) remain unclear. Using data from The Cancer Genome Atlas, Gene Expression Omnibus, Gene Set Cancer Analysis, cBioPortal, GeneMANIA, String, MethSurv and starBase database, we identified vascular endothelial growth factor B (VEGFB) as a key gene associated with COAD prognosis, with its abnormal expression linked to methylation dysregulation. In vitro experiments confirmed VEGFB expression was significantly higher in colon cancer tissues compared to normal tissues, as shown by Real-time quantitative PCR and immunohistochemistry. Cell Counting Kit-8 and colony formation assay showed that decreased VEGFB expression in SW480 cells resulted in decreased cell viability and proliferation ability. Scratch assay showed that VEGFB downregulation impaired SW480 cell migration. In addition, our research suggests that VEGFB not only promotes angiogenesis but is also involved in the tumor microenvironment and immune regulation. The SHNG17-miR-375-VEGFB regulatory axis provides a potential therapeutic target for COAD, highlighting VEGFB's role in immune activation during anti-angiogenic therapy and potential reversal of drug resistance.
<P>PROBLEM TO BE SOLVED: To provide a preparation capable of readily being taken into the body by making it small-size without lowering medicinal benefits and a preparation improved in its solubility, in a therapeutic medicine for hyperlipemia in which a composition of fenofibrate with polyethylene glycol is formulated.  <P>SOLUTION: The solid dispersion is prepared by melt-mixing fenofibrate with polyethylene glycol and solidifying the mixture. In the solid dispersion, the ratio of fenofibrate to the solid dispersion is ≥50 mass%. A capsule or a tablet comprises the solid dispersion. The capsule is obtained by mixing the solid dispersion with a crystalline cellulose and packing the mixture into a capsule or the capsule is obtained by mixing the solid dispersion with the crystalline cellulose, sodium lauryl sulfate and magnesium stearate and packing the mixture into a capsule. The therapeutic agent for hyperlipemia comprises the solid dispersion as an active ingredient.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Reduced-sodium salts are a proven method for reducing sodium intake and lowering blood pressure. No studies to date have tested the effects of sodium reduction on the rise in blood pressure with age during adulthood or the critical periods of childhood and adolescence. The investigators want to explore whether reducing dietary sodium intake using reduced-sodium salt in comparison to regular salt, will attenuate the rise in blood pressure with age. This feasibility study aims to determine the feasibility of implementing a reduced-sodium iodised salt (66% potassium chloride, 34% sodium chloride) intervention in Nigeria. Specifically, the investigators will explore the feasibility of recruiting households with at least one child or adolescent 6-17 years of age and one adult ≥18 years, the acceptability of the reduced-sodium salt intervention, adherence to study procedures and data collection methods, and the effect of the reduced-sodium salt intervention on blood pressure. Secondary outcomes include household eligibility, household composition, willingness to engage in monthly follow-up visits in a longer-term trial, blood pressure, urinary sodium and potassium concentrations, height and weight. This study will be used to inform a large-scale intervention trial comparing the effects of reduced-sodium salt versus regular salt on the rise in blood pressure with age. The study will be conducted in two rural communities in Nigeria and will recruit 30 households (approximately 150 participants). All participants will be provided with the reduced-sodium salt intervention to replace all regular salt used for cooking, seasoning and food preservation over a 2-month period; there will be no control. Follow-up visits will be at 1 month and 2 months after the baseline visit, conducted either at the home or a local community healthcare centre.
FIELD: medicinal polymers. SUBSTANCE: invention relates to enterosorbent based on microcrystalline cellulose that can be used for treating acute and chronic infections, exogenous and endogenous intoxications, disturbances of the fat and other types of metabolism and to microcrystalline cellulose technology. Powdered enterosorbent, in particular, contains 50-60% of microcrystalline cellulose particle fraction 4-100 mcm and 40-50% of fraction 100-400 mcm. Enterosorbent is prepared by hydrolysis of native or extracted from vegetable tissues cellulose with 0.5-1.5% aqueous mineral acid solution at 110-130 C for 5 to 15 min followed by drying, disintegration, and fractionation to pick of microcrystalline cellulose particle fraction 40-400 mcm. EFFECT: increased sorption capacity. 4 cl, 2 tbl, 2 ex
The invention relates to a bispecific antibody targeting TfR1 and a soluble antigen. The inventors demonstrate that the unique mode of interaction of the bispecific antibody with TfR1 increases its persistence in vivo through an FcRn-like mechanism. It has been demonstrated on MCF7 cell line that the bispecific antibody induces soluble antigen (IL6) uptake through TfR1 mediated endocytosis. Effects of the bispecific antibody on XG6 cell lines viability have been demonstrated, notably on iron and IL-6 deprivation. Hence, the inventors design an improved sweeping antibody which can specifically target tumors and inflammatory cells expressing TfR1. By its unique mode of interaction with TfR1, its ability to induce soluble uptake antigen through TfR1 mediated endocytosis and its capacity to deprive cells of iron, known for being required in tumors growth and progression and development of inflammatory pathologies, the bispecific antibody can be used in the treatment of cancer and inflammatory pathologies.
Patients receive whey protein supplementation as in Arm I. Patients also undergo a home flexibility program 3 times per week, consisting of the same static stretching exercises performed after RT. After 12 weeks, patients may undergo the RT program as in Arm I.
Cyclic nucleotide phosphodiesterases (PDEs) modulate neurohormonal regulation of cardiac function by degrading cAMP and cGMP. In cardiomyocytes, multiple isoforms of PDEs with different enzymatic properties and subcellular locally regulate cyclic nucleotide levels and associated cellular functions. This organisation is severely disrupted during hypertrophy and heart failure (HF), which may contribute to disease progression. Clinically, PDE inhibition has been seen as a promising approach to compensate for the catecholamine desensitisation that accompanies heart failure. Although PDE3 inhibitors such as milrinone or enoximone can be used clinically to improve systolic function and relieve the symptoms of acute CHF, their chronic use has proved detrimental. Other PDEs, such as PDE1, PDE2, PDE4, PDE5, PDE9 and PDE10, have emerged as potential new targets for the treatment of HF, each with a unique role in local cyclic nucleotide signalling pathways. In this review, we describe cAMP and cGMP signalling in cardiomyocytes and present the different families of PDEs expressed in the heart and their modifications in pathological cardiac hypertrophy and HF. We also review results from preclinical models and clinical data indicating the use of specific PDE inhibitors or activators that may have therapeutic potential in CI.
BACKGROUND/AIM: The most commonly prescribed anti-seizures medications (ASMs) for the treatment of epilepsy are currently topiramate, zonisamide, lacosamide, carbamazepine and levetiracetam. The objective of this study was to examine the correlation between preoperative, intraoperative, and postoperative metabolic acidosis and the use of ASMs prior to craniotomy operations.
MATERIALS AND METHODS: This retrospective cross-sectional study evaluated patients who underwent intracranial surgery with craniotomy under general anaesthesia between May 2020 and April 2023 and used ASMs. The patients were classified into four groups based on the pharmacological mechanisms of action of the ASMs administered before intracranial surgery (Group-I, zonisamide or topiramate; Group-II, lacosamide; Group-III, carbamazepine; Group-IV, levetiracetam). Metabolic acidosis severity was defined based on base excess (BE) levels: mild (-3 to -5), moderate (-5 to -10), and severe (below - 10). The study investigated the correlation between ASMs and the severity of metabolic acidosis in preoperative, intraoperative, and postoperative blood gas measurements.
RESULTS: Out of 35 patients, 24 patients underwent intracranial surgery and 11 patients underwent epilepsy surgery. There were statistically significant differences in the severity of metabolic acidosis between preoperative (p < 0.001), intraoperative (p < 0.001) and postoperative (p = 0.01) groups. The preoperative mean BE of group-I was - 4.7, which was statistically lower than that of group-III (p = 0.01) and group-IV (p < 0.001). Intraoperatively and postoperatively, group-I had a mean BE of -7.5 and - 3.2, respectively, which was statistically lower than that of groups II (p = 0.007; p = 0.04), III (p = 0.002; p = 0.03), and IV (p < 0.001; p = 0.009). There was no statistically significant difference in BE between groups II, III and IV at all three time points. Group I had the lowest BE at all three time points. Intraoperative bicarbonate was administered to all patients in group I, whereas no intraoperative bicarbonate was required in the other groups. In group I, 50% of patients required postoperative intensive care.
CONCLUSION: The use of ASMs in patients undergoing surgery is important in terms of mortality and morbidity. Topirimat and zonisamide are ASMs that can cause preoperative, intraoperative and postoperative metabolic acidosis. Patients receiving topirimat or zonisamide are particularly susceptible to metabolic acidosis. Special care should be taken in the management of anaesthesia in patients receiving these drugs, and monitoring of the perioperative metabolic status is essential.
BACKGROUND: The increasing awareness of women's health issues, specifically pelvic organ prolapse (POP) and urinary incontinence (UI), has spurred a surge in patients seeking specialised advice for these conditions, necessitating modern diagnostic approaches for such issues. This study explored the diagnostic utility of translabial ultrasound for POP, emphasising its correlation with clinical assessments based on International Continence Society (ICS) criteria.
METHODS: Seventy-one patients with POP Quantification System (POP-Q) stage 0-IV with or without UI were prospectively enrolled at Jagiellonian University Medical College between 2014 and 2016. The study objectives included evaluating diagnostic accuracy and concordance across pelvic compartments, correlating the diagnoses with patient-reported symptoms, and identifying variables contributing to diagnostic discrepancies.
RESULTS: Translabial ultrasound identified POP in 74.5% of the patients, aligning closely with clinical evaluations. Concordance was the highest in assessments performed in the medial compartment (85.8%), while assessments performed in the anterior (29.6%) and posterior (29.6%) compartments showed higher rates of discrepancies. Correlation analyses showed varying associations, with the posterior compartment exhibiting the least pronounced correlation (R = 0.72, p < 0.0001). Self-perceive POP showed no discernible differences in relation to ultrasonographic and clinical assessments. Among the respondents, 55.9% reported experiencing the sensation of POP. Mean POP levels determined using the two approaches precisely matched in 46.5% of these cases. Discrepancies involved variables such as self-perceived POP, number of deliveries, child weight at birth, UI, and sexual activity.
CONCLUSIONS: Translabial ultrasound showed robust correlation with clinical assessments for evaluating POP, especially for defining defects and facilitating treatment-related decision-making. Our findings highlight the reliability of this method, particularly for assessments in the medial compartment. The evidence did not indicate the superiority of either method in detecting POP disorders for symptomatic versus asymptomatic patients. Significantly, a higher POP-Q measurement in clinical examination was correlated with greater sexual activity.
BACKGROUND: Patients with cancer (PwC) who undergo specific treatments reported greater fatigue and reduced functional capacity as predominant outcomes, compromising their QoL during and following the treatment. Prehabilitation intervention, provided after diagnosis and before treatments, is to optimize the physiological reserve and address modifiable risk factors before surgery or chemotherapy to improve post-treatment results. The primary aim of this study is to obtain a common line of efficacy compared with prehabilitation treatment; the secondary endpoint is to assess the methodological quality of the studies eligible in the review.
METHODS: The systematic review was conducted from September to February 2024, in accordance with PRISMA guidelines. Databases consulted were MEDLINE, Scopus, Web of science and CINAHL, RCTs related to Prehabilitation intervention on PwC were included. The methodological quality of the included studies was assessed through the RoB2 Cochrane tool and the PEDro scale. Meta-analysis was performed to estimate relative treatment effects among evaluated outcomes.
RESULTS: Forty-two studies were included in the systematic review, 13 were included in the quantitative analysis. The results of the studies reporting reduced postoperative hospital stay, improved endurance, muscle strength, respiratory function, quality of life, and urinary incontinence. Critical analysis of the articles using the PEDro scale revealed 28 RCTs with a good rating, 9 with a fair rating, and 5 with a poor rating; in contrast, the Cochrane RoB2 tool revealed that all articles were at high risk of bias. Meta-analysis showed statistically significant values for 6MWT (38.53, 95%CI 33.03 - 44.04); HADS-depression (-0.71, 95%CI -0.93 -0.49) and HADS-anxiety (-0.49, 95%CI -0.76 -0.23).
CONCLUSIONS: Prehabilitation represents a specific intervention that aims to improve postoperative outcomes in fragile patients undergoing surgery, increasing their preoperative physiological reserve in anticipation of the stress they will face and facilitating the postoperative recovery of functional capacity. Prehabilitation is a good intervention to use, especially in terms of functional capacity and mental health, the latter being very impactful in terms of reduced levels of anxiety and depression. These data make it possible to justify supportive intervention by physical therapists aimed at improving and restoring health-related QoL especially in the short term.
The invention belongs to the technical fields of biological medicine and molecular biology, and particularly relates to application of NONO in slowing down calcification of a blood vessel medium membrane by inhibiting transcription of BMP 2. The invention discovers that NONO expression is obviously reduced in calcified blood vessels of mice through research. Meanwhile, smooth muscle cell-specific NONO knockout mice are more susceptible to vascular media calcification, which is manifested by increased calcification and calcium deposition. Likewise, smooth muscle cell-specific NONO knockdown aggravates the degree of calcification of aortic annulus extracted from mice. In vitro, knockout of NONO aggravates high phosphorus-induced osteogenic differentiation and calcium deposition in vascular smooth muscle cells, while overexpression of NONO improves this phenomenon. Mechanically, NONO targets BMP2, inhibiting its gene transcription. The NONO is a novel negative regulation factor for calcification of the blood vessel media, so that the NONO has good potential practical application value.
This group is provided with biomarker feedback on child exposure to secondhand smoke. Active participants receive 5 counseling sessions from a trained research counselor; 3 sessions in the home and 2 by phone. The counseling sessions focus on changing smoking behaviors and/or other behaviors that impact smoking.
PURPOSE:To improve the efficiency for forming liposome by removing a solvent from a soln. in an org. solvent of lipid for forming liposome film by distillation, prepg. a uniform suspension by shaking the distillation residue after adding an aq. soln., etc. thereto, and ejecting the suspension under high pressure. CONSTITUTION:Lipid for forming liposome film is dissolved in an org. solvent. After distilling off the solvent from the soln., the distillation residue is shaken or subjected to ultrasonic wave treatment after addition an aq. soln. having high viscosity. Thus, uniform suspension is obtd. Then, inert gas is diffused sufficiently into the suspension by pressurizing the suspension by the inert gas, then the suspension is ejected at high pressure through a fine space to obtain the liposome. Particularly suitable lipid for forming the liposome film is phospholipid such as lecithin, phosphatidyl ethanolamine, etc. Suitable viscosity of the aq. soln. to be added to the above described residue is 10-3,000cp (4 deg.C).
The effectiveness of CUVRIOR for the treatment of adult patients with stable Wilson's disease who are decoppered and tolerant to penicillamine was demonstrated in a phase 3 trial (Trial 1). In addition, the safety and effectiveness of CUVRIOR in Wilson's Disease is further supported by studies of another trientine product in patients intolerant to penicillamine.

Trial 1 was a randomized, active-controlled, multi-center, non-inferiority study (NCT03539952) conducted in 53 adult patients with Wilson's disease. The objective was to compare treatment with CUVRIOR to treatment with penicillamine. All patients had been receiving penicillamine for at least 1 year prior to study entry, were adequately controlled and tolerating penicillamine, and had a serum NCC level between ≥ 25 and ≤ 150 mcg/L.

At the start of the study, patients entered a 12-week baseline period and continued to receive their established total daily dosage of penicillamine for 12 weeks. At Week 12, patients were randomized to either remain on penicillamine (N=27) or to switch to CUVRIOR (N=26) for the 24-week post-randomization period (i.e., Week 12 through Week 36). For patients switching to CUVRIOR, where possible, the initial total daily dosage was determined as the trientine base in mg that was the same as the patient's total daily dosage in mg of penicillamine. Where a direct mg to mg conversion was not possible, the total daily dosage of CUVRIOR was rounded to the nearest 150 mg of trientine base (300 mg trientine tetrahydrochloride salt) to the penicillamine total daily dosage. The dosage was permitted to be adjusted depending on clinical response. The mean CUVRIOR total daily dosage was 1,800 mg. Upon switching from penicillamine to CUVRIOR, 3 patients switched to a CUVRIOR total daily dosage < 900 mg, 9 patients to a total daily dosage between 900 mg and 1,800 mg, and 14 patients to a total daily dosage of 1,800 mg or greater. Three out of 26 patients increased and one patient reduced the total daily dosage across the 24-week post-randomization period.

The results are presented in Table 5. The primary efficacy endpoint was the mean serum non-ceruloplasmin copper (NCC) level at 24 weeks post-randomization (Week 36). At Week 12 (prior to initiation of randomized treatment), the mean (95% CI) NCC levels in the penicillamine and CUVRIOR arms were 77 mcg/L (66; 88) and 66 mcg/L (55; 76), respectively. The mean NCC level at Week 36 as measured using an assay not commercially available was similar in patients receiving CUVRIOR and in patients receiving penicillamine. However, the mean 24-hour urinary copper excretion (UCE) at Week 36 was lower in patients receiving CUVRIOR as compared to patients receiving penicillamine. A decrease in UCE has been observed when switching patients from penicillamine products to trientine products. All patients in both treatment arms were considered clinically stable as determined by an adjudication committee at Week 36.
The present disclosure provides a fitness pole. The exercise bar includes a handle tube having a longitudinal bore. The handle tube has a first end and a second end. The central shaft has an outer surface. The central shaft fits through the longitudinal bore, exposing a first end portion of the central shaft at the first end of the handle tube and a second end portion of the central shaft at the second end of the handle tube. A sensor is disposed on a mounting section of the outer surface of the central shaft between a first portion and a second portion of the central shaft. The processor is arranged inside the body-building rod. The sensor is in electronic communication with the processor in the exercise bar.